At the end of this post you'll find a copy of an extended nicotine patch use cessation study story making news this week. Lapse and relapse gobbledygook aside, what the story does NOT disclose to smokers is that only 2 of 282 participants who wore the nicotine patch for 24 weeks were able to stop smoking for an entire year, an extremely dismal one-year continuous cessation rate of 0.7. In fact, among the 286 study participants who used the patch for the standard 8 week period, the 1 year rate was slightly higher, with 3 participants able to stop smoking for an entire year, a rate of 1.0%. If true, how is the below article able to paint this study as an extended patch use victory?
Why so horrible? I believe that this study stands for the proposition that the human brain cannot downregulate the number of a4b2-type nicotinic receptors nor restore natural receptor sensitivities while nicotine continues to arrive. It means that whether nicotine, bupropion or varenicline, that eventually artificial dopamine pathway stimulation comes to an end. At some point the mind must endure some degree of emotional turmoil associated with ending artificial stimulation.
Another critical factor at work is the tremendous damage done by teaching nicotine addicts that nicotine is medicine and its use therapy. Imagine telling alcoholics or heroin addicts such rubbish. It's a death sentence. Where is the sanity in declaring a nicotine addict to have successfully quit when nicotine is still circulating inside their bloodstream?
This paper acknowledges that the senior author had consulting ties to GlaxoSmithKline, the maker of the Nicoderm CQ patches used in the study. Nearly all medical journals now print financial conflicts near the end of the study, just before the list of study references. What does our common sense tells us? If we had previously accepted money or funding from a major nicotine gum maker and our new NRT study finding seriously damaged pharm industry nicotine gum sales, would we ever again receive pharm industry study funding or industry consultancy fees? We'd be forced to either learn to spin negative study data into positive findings or find a new line of work.
A reading of the full-text of the last few major quitting studies evidence extreme creativity in attempting to turn failure into new NRT product marketing opportunities (my review of the lozenge + patch study http://whyquit.com/pr/111209.html and the pre-quitting patch study http://whyquit.com/pr/071209.html). Here in this extended patch use study the authors employed creative definitions that are rather forgiving of smoking relapse, definitions that can only be appreciated by reading the full-text, definitions we won't see used when the study's objective is to create massive efficacy victories over stimulation deprived placebo participants.
If you have not yet signed the petition requesting honest smoking cessation studies I would encourage you to consider doing so. Together we can make a difference!
Breathe deep, hug hard, live long,
John (Gold x10)
Ann Int Med:
More smokers kick the habit with extended
nicotine patch therapy, Penn research shows
February 3, 2010
Longer use of nicotine patch improves abstinence from cigarettes, helps smokers quit again after relapse
New research from the University of Pennsylvania School of Medicine may help more smokers keep their New Year's resolution by helping them quit smoking. Extended use of a nicotine patch â€“ 24 weeks versus the standard eight weeks recommended by manufacturers â€“ boosts the number of smokers who maintain their cigarette abstinence and helps more of those who backslide into the habit while wearing the patch, according to a study which will be published in the February 2 issue of Annals of Internal Medicine.
"Our data suggest that the many smokers who relapse while trying to quit will be especially helped by extended treatment, which appears to make it easier for smokers to 'get back on the wagon' after a small smoking slip, instead of having it turn into a full-blown relapse," says lead author Robert Schnoll, PhD, an associate professor of Psychiatry at Penn. "We know that tobacco dependence is a chronic, relapsing condition that may require extended treatment, and we hope our research efforts will encourage physicians to recommend to their patients that they use nicotine patches for a longer duration."
Schnoll and senior author Caryn Lerman, PhD, a Mary W. Calkins Professor of Psychiatry and Deputy Director of the Abramson Cancer Center, studied 568 adult smokers who smoked 10 or more cigarettes per day for at least the past year. At the end of the 24-week study, smokers who used a nicotine patch throughout the whole trial were about two times as likely to have been successful in their quitting attempts than those who received a placebo patch after the eighth week of the study: 31.6 percent of extended therapy participants had not smoked in the past seven days, compared to 20.3 percent of standard therapy participants. More than nineteen percent of participants on the extended patch regimen did not smoke at all, even a puff, during the trial, compared to 12.6 percent of those who stopped getting the active transdermal therapy after week eight. The benefits also extended to those who relapsed during the study: The smokers on extended therapy abstained from cigarettes for longer, and were more likely to stop smoking again even if they relapsed.
When the researchers followed up with participants at week 52, however, they found no difference in the main measures of smoking abstinence between those who had used the extended patch therapy (14.5 percent) and those who used the standard regimen (14.3 percent), though the extended patch users were more likely (29.1 percent vs. 21.3 percent) to have reported no periods of smoking lasting more than 7 days in a row -- during the entire year.
Though drug therapies including Zyban and Chantix produce similar results to extended patch therapy, the authors say their findings provides a cessation option to more smokers, since nicotine patches are available over the counter and can be used even by people with seizure disorders or mental health problems like depression, who are generally advised not to use those drugs. The authors estimate that the cost per quitter for extended therapy costs $2,482, which is similar to other drug-related cessation aids. However, cost may remain a barrier to accessing proven smoking cessation tools: Just 8.6 percent of U.S. health insurers fully cover the cost of nicotine patches, and only 33 states pay for Medicaid patients to use the patch.
The new research is part of an ongoing effort in Penn's Center for Interdisciplinary Research on Nicotine Addiction learn more about the genetic underpinnings of nicotine addiction â€“ and tailor smoking cessation approaches to individual smokers. In addition, to buoy smokers' long-term success following extended nicotine patch therapy, the authors suggest combining cessation strategies, such as pairing extended patch use with more intensive counseling or having smokers begin using nicotine patches before their quitting attempt begins.
"While we have documented that extended therapy is more efficacious overall than standard therapy, not everyone benefits equally," Lerman says. "Therefore, our team is using genetic approaches to identify smokers who will achieve the greatest benefit from an extended or maintenance therapy approach."